Preferred Label : AC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen;
NCIt synonyms : AC Followed by Paclitaxel Pertuzumab Trastuzumab; Doxorubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Paclitaxel; AC Followed by Pertuzumab Trastuzumab Paclitaxel; AC Followed by Paclitaxel Trastuzumab Pertuzumab; Doxorubicin/Cyclophosphamide Followed by Pertuzumab Trastuzumab Paclitaxel; AC-Pertuzumab Trastuzumab Paclitaxel; AC Followed by Pertuzumab-Trastuzumab-Paclitaxel Regimen;
NCIt related terms : ddAC-THP (Paclitaxel); AC-THP (Paclitaxel) (trastuzumab-dkst); AC-THP (Paclitaxel) (trastuzumab-qyyp); AC-THP (Paclitaxel) (trastuzumab-pkrb); AC-THP (Paclitaxel) (trastuzumab-dttb); AC-THP (Paclitaxel) (trastuzumab-anns); AC-THP (Paclitaxel) (trastuzumab-zerc); AC-THP (Paclitaxel) (trastuzumab-herw);
NCIt definition : A regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab,
and paclitaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive
breast cancer.;
NCIt note : Source: NCCN Guidelines 2017;
NCI Metathesaurus CUI : CL525012;
Codes from synonyms : 63533; 128939; 129424; 129327; 128842; 129230; 129133; 129036;
Origin ID : C138032;
UMLS CUI : C4527340;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
